Wedbush boosted their price target on shares of Anacor Pharmaceuticals (NASDAQ: ANAC) from $10.00 to $20.00 in a research note issued on Friday, TheFlyOnTheWall.com reports. The firm currently has an “outperform” rating on the stock.
Separately, analysts at Canaccord Genuity cut their price target on shares of Anacor Pharmaceuticals from $9.00 to $5.00 in a research note to investors on Wednesday, January 30th. They now have a “buy” rating on the stock.
Anacor Pharmaceuticals (NASDAQ: ANAC) traded up 27.27% on Friday, hitting $6.16. Anacor Pharmaceuticals has a 52-week low of $3.00 and a 52-week high of $7.18. The stock’s 50-day moving average is currently $3.61. The company’s market cap is $219.1 million.
Anacor Pharmaceuticals (NASDAQ: ANAC) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.36) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.45) by $0.09. The company had revenue of $3.28 million for the quarter, compared to the consensus estimate of $3.25 million. During the same quarter last year, the company posted ($0.52) earnings per share. Anacor Pharmaceuticals’s revenue was up 26.6% compared to the same quarter last year. On average, analysts predict that Anacor Pharmaceuticals will post $-1.58 earnings per share for the current fiscal year.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.